Farmas USA

Gracias kiyo!
A guardar para leer con calma

OCAT

Por cierto, que la presentación de hoy me había confundido con la de la semana que viene, que creo que será más importante, el día 9 en la 2nd Cell and Gene Therapy Conference de Philadelphia

Erin A. Kimbrel
Director, Translational Research
Ocata Therapeutics

Pluripotent stem cells (PSCs) have important clinical potential in regenerative medicine given their ability to differentiate into any cell type in the body. While inefficient differentiation and concerns over potential tumorigenicity have hindered their clinical development, the first wave of PSC-based therapies is now being tested in clinical trials and showing safe application in humans. Additional PSC-derived products are being developed for treating a variety of diseases, including autoimmune disorders. Through a unique differentiation and manufacturing process, we have established a platform for the generation of highly potent immunomodulatory cells termed hemangio-mesenchymal cells, or HMCsTM from pluripotent stem cells. Preclinical data show strong therapeutic activity for HMCs in models of lupus nephritis, Crohn’s, multiple sclerosis, and autoimmune uveitis, principally through the secretion of paracrine-acting factors that alter the behavior of innate and adaptive immune cells. Starting from a pluripotent stem cell source, HMCs are both youthful and replenishable, representing the earliest stage of biological development. Preclinical evidence shows that these attributes afford HMCs greater potency than mesenchymal stromal cells, which are derived from primary tissue sources like bone marrow and umbilical cord. Moreover, banks of genotypically identical HMCs can be generated on a commercial scale without the need for extended in vitro culture or use of multiple donors, which facilitates a consistent final product. Various stages in the development of a pluripotent stem cell-based product like HMCs- from disease model testing to quality control in manufacturing to safety and biodistribution - will be addressed.

Key points:
1. The current status of pluripotent stem cell (PSC)-based products in clinical trials
2. Preclinical evaluation of HMCs, a PSC-based product for treating autoimmune diseases
3. A comparison between the use of PSCs and primary tissues as sources for cell-based products
4. GMP lot release considerations and safety testing for PSC-based therapies

https://www.gtcbio.com/conferences/cell-gene-therapy-agenda

Cómo pensamos que puede ir el dólar en los próximos meses?

Nos prometiste 6,20$ para hoy... Donde están? :((

Ya me parecía raro, porque lo de hoy es el típico poster en un stand con otras farmas por ahí pululando con sus posters, no? Bueno, yo no vi que fuera conferencia, coloquio, o algo similar. Eso sí, el Sr Lanza en primera, volando hasta Viena para ponerse fino de comida y otros vicios a costa del sufrido accionista. Quiero mis 6,20$ o que mande al becario para ahorrarnos pasta!!! jeje

OCAT

Esto es un hilo de farmas. Tienes hilos de forex con gente muy buena que seguro te dan una opinión bastante acertada. Aquí solo ponemos velas y hacemos oraciones para que se acerque a la paridad con el euro.

https://www.rankia.com/foros/bolsa/temas/1525847-forex-pulso-mercado

O incluso más allá de la paridad....jajajja

No hay que abusar de las plegarias, que luego los dioses se cabrean y nos echan 7 plagas o lo que les venga en gana... :))

Creación empleo agosto: 173.000 estimado 223.000
Tasa de paro: 5,1% estimada 5,2%

Creación por debajo de previsiones, a ver si anima los mercados, al pensar que aleja un poco el inicio de subidas de tipos...